We report the successful transplantation of human hepatocytes in immunodeficient, fumarylacetoacetate hydrolase-deficient (fah ؊/؊ ) mice. Engraftment occurs over the entire liver acinus upon transplantation. A few weeks after transplantation, increasing concentrations of human proteins (e.g., human albumin and human C3a) can be measured in the blood of the recipient mouse. No fusion between mouse and human hepatocytes can be detected. Three months after transplantation, up to 20% of the mouse liver is repopulated by human hepatocytes, and sustained expression of lentiviral vector transduced gene can be observed. We further report the development of a hepatocyte transplantation method involving a transcutaneous, intrahepatic injection in neonatal mice. Human hepatocytes engraft over the entire injected lobe with an expansion pattern similar to those observed with intrasplenic transplantation.
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fumarylacetoacetate hydrolase ͉ hepatocyte transplantation ͉ lentivirus ͉ recombination activating gene 2 ͉ IL-2 receptor common gamma chain I n vitro cultures of primary cells often do not reflect their biological functions in the organism. For instance, cultured human hepatocytes display a different gene expression profile than hepatocytes in the liver. Therefore, substantial efforts have been made to repopulate murine livers with human hepatocytes. Yet the ability to propagate specialized human cells with intact biological functions in experimental animal models remains technically challenging.
Until recently, only the urokinase type plasminogen activator (uPA) mouse model was permissive for repopulation of human hepatocytes. This mouse model, developed to study bleeding disorders, contains an additional copy of uPA expressed from an albumin promoter. As anticipated, the mouse had increased fibrinolysis, but hepatotoxicity was also observed, which usually led to the death of pups because of intestinal bleeding or liver failure (1) . Surprisingly, the few mice that survived showed clonal expansion of hepatocytes that had a deletion of the uPA transgene (1). This result confirmed prior observations that hepatocytes with a growth advantage can selectively expand. A few years later, congenic and xenogenic (rat and woodchuck) hepatocyte transplantation was reported (2) (3) (4) . Similarly, human hepatocytes permissive to hepatitis B and C infection were transplanted into uPA mice (5, 6) . Although the uPA mouse is permissive to xenotransplantation of hepatocytes, high mortality because of bleeding is a major disadvantage and consequently limits surgery needed for transplantation. Moreover, transplantation needs to be performed within a narrow timeframe (5-12 days after birth), and the somatic reversion can mask a successful engraftment. Furthermore, the mouse breeds poorly and remains unhealthy after repopulation with human hepatocytes (7) . Grompe et al. (8) developed a murine model for hereditary tyrosinaemia type I, which has a deletion in the enzyme fumarylacetoacetate hydrolase (FAH) and results in a toxic accumulation of tyrosine catabolites within hepatocytes. This mouse is considered to be a superior repopulation model because spontaneous reversion does not occur with the full deletion of exon 5. In addition, the compound 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione (NTBC) blocks the enzyme hydroxy-phenylpyruvate dioxygenase upstream of FAH and therefore prevents the accumulation of hepatotoxic metabolites. Because repopulation with congenic hepatocytes is robust (9), we decided to use the fah Ϫ/Ϫ mouse to transplant human hepatocytes.
Recently, Azuma et al. (10) reported that immunodeficient fah Ϫ/Ϫ mice can be transplanted with human hepatocytes (10) . However, engraftment only was observed in those recipients that were first treated with an adenovirus-expressing uPA. Here we reproduce their observations of repopulation of human hepatocytes into the immunodeficient (lacking B, T, and NK cells), fah Ϫ/Ϫ mouse, with the additional modification that uPA expression is not required. The transplanted human hepatocytes show sustained expression of the lentiviral vector-transduced transgene.
We further report the development of a simple, intrahepatic transplantation method that leads to efficient repopulation of human hepatocytes into neonatal mice.
Results

Characterization of Transplanted Human Hepatocytes.
For transplantation of human hepatocytes, we first generated a suitable immunodeficient mouse by crossing the fah Ϫ/Ϫ mouse with the recombination activating gene 2 KO (rag-2 Ϫ/Ϫ ) mouse, which is depleted of mature B and T lymphocytes. We further crossed this double KO with the IL-2 receptor, common ␥-chain KO (il-2rg Ϫ/Ϫ ) mouse, which has impaired B and T cell development and a complete block of NK cell development (11, 12) . These triple KO mice allow more efficient engraftment of human cells (13) .
We further blocked two other components of the immune system by drug treatment. The first one, the complement system, was inhibited by i.p. injection of the protease inhibitor nafamostat mesilate (Futan) (14) . The second involved the eradication of Kupffer cells, which are liver macrophages, by treating the mice before transplantation with liposomes containing clodronate, a biphosphonate known to efficiently deplete Kupffer cells (15) . Human hepatocytes from the same donor were transplanted by intrasplenic injection (16) into animals of all experimental groups. After transplantation, NTBC was withdrawn, and mice were monitored every second day for changes in body weight. A constant or increasing body weight reflects a balanced hydration status and is an indirect indicator of successful engraftment. Fah Ϫ/Ϫ mice that did not receive hepatocyte transplantation and are withdrawn from NTBC progressively lose weight and die within 4-10 weeks. Data from six independent transplantations in animals with different immune status confirm that depletion of B, T, and NK cells is necessary and sufficient for successful transplantation of human hepatocytes.
Engrafted human hepatocytes were analyzed for FAH expression in the liver, which is indicative of human cell engraftment because the recipient mice have a fah gene deletion. FAHpositive human hepatocytes could be detected from periportal to centrilobular over the whole liver acinus in all liver lobes ( Fig.  1A ). Cells were found in small clusters, reflecting the selective expansion after successful engraftment. Three months after transplantation, some areas of the murine liver had 50% human hepatocytes (Fig. 1C ). However, the extent of repopulation in different areas of the same liver was variable: Ϸ10-20% of the mouse liver was repopulated with human hepatocytes. Interestingly, apoptotic mouse hepatocytes were rarely found in between the human cell clusters, whereas in other parts of the sections apoptosis was common if the mouse did not receive NTBC (data not shown). As human cell clusters expanded over time, mouse cells seemed to expand in between their human counterparts, leading to the mixed clusters of human and mouse cells.
Because it was difficult to morphologically distinguish human from mouse hepatocytes within the cluster, we wanted to determine whether transplanted human hepatocytes underwent fusion with the resident mouse hepatocytes. Therefore, we undertook in situ hybridization of the transplanted hepatocytes using human-and mouse-specific centromere sequences. Fig. 2 shows an absence of fusion as judged by the lack of overlap of staining between mouse and human markers ( Fig. 2C ). Human hepatocytes were detected in each of the seven lobes, with a slight preference for subcapsular localization. However, macroscopically those clusters were not distinguishable from murine tissue.
Transplanted mice were further analyzed for secreted human serum components. Fig. 3A shows measurements of human plasma C3a, a member of the complement cascade and human serum albumin (Fig. 3B ). Both human proteins increased over time to a comparable extent, whereas control animals (fah Ϫ/Ϫ / rag-2 Ϫ/Ϫ double KO) transplanted with hepatocytes from the same donor had background levels. Cryopreserved hepatocytes from the same donor also could be successfully engrafted into triple KO mice, albeit with reduced viability (60% trypan blue).
We next tested whether human hepatocytes can be transduced in vitro with a lentiviral vector containing a transgene and express it in vivo after transplantation. Two months after transplantation, Lenti-GFP (lentivirus carrying a GFP cassette) transduced human hepatocytes showed robust expression of the transgene (Fig. 4 ).
We conclude that transplanted and expanded human hepatocytes display normal biological functions and can express foreign genes. Neonatal Transplantation. The neonatal liver has more dividing hepatocytes than the adult liver. This proliferative environment may be beneficial for the expansion of engrafted human hepatocytes. Furthermore, neonatal mice cannot be intrasplenically transplanted. Therefore, we developed a neonatal transplantation technique for human hepatocytes, which consists of a transcutaneous injection into the left lower lobe (LLL) of the neonatal liver (for details, see Materials and Methods). Successful engraftment was assessed 2 months after transplantation by measurement of human protein in the murine blood and immunohistochemistry of the liver. Fig. 5 shows the congruent expression of human-specific cytokeratin (CK-18) and FAH (D-F). Eleven of 15 (73%) animals engrafted human hepatocytes in the liver. Interestingly, FAH immunostaining showed clusters of human hepatocytes not only at the site of injection, but over the entire LLL (Fig. 5A ). These clusters were not observed in other lobes of the mouse liver, with the exception of one mouse that had clusters in the right upper liver lobe, which is just next to the LLL. Human hepatocytes were integrated in between the mouse cells just like we observed with the intrasplenically transplanted adult mice and could not be distinguished from the latter by H&E staining (Fig. 5C ).
Discussion
We report the development of a method for successful repopulation of human hepatocytes in mice lacking B cells, T cells, and any residual NK cell activity. Our transplantation success rate for adult animals was between 45% and 100%. Surprisingly, even cryopreserved hepatocytes with a 60% viability could be transplanted into three of four mice. Similarly, the age (36-71 years) or sex of the donor also was not critical. Presently, it is not clear what factors determine transplantation efficiency.
Although it is difficult to measure the exact extent of the contribution of human hepatocytes in the chimeric mouse liver, by examining the sections of transplanted liver for humanspecific markers, we estimate 10-20% being of human origin. The maximal repopulation rate may be higher at later time points (after 3 months). Depending on the total amount of cells engrafted, the focal expansion of human hepatocytes in the fah Ϫ/Ϫ mouse could take longer. Furthermore, focal expansion of human hepatocytes might slow down after a few weeks because, within the same liver acinus, the tyrosine-dependent toxicity on mouse hepatocytes decreases. This hypothesis is supported by the observation that less apoptosis of mouse hepatocytes is encountered around human cell clusters than in the remainder of the liver during selection (withdrawal of NTBC). Consequently, the human cells gradually lose their growth advantage over the mouse cells. This finding also would explain why human hepatocytes in the fah Ϫ/Ϫ mouse do not expand in continuum, as was shown for the uPA mouse (5, 7), but are interspersed within mouse hepatocytes ( Figs. 1 and 5) . Therefore, the chimerism is not only observed on the organ level, but in every liver acinus. In the uPA mouse, the growth disadvantage of the murine hepatocytes is sustained as long as the transgene is expressed. In the fah Ϫ/Ϫ mouse, however, this growth disadvantage depends on the absorbed tyrosine and the use of NTBC.
The chimerism on the acinar level with the ''patchy'' immunostaining (CK-18 and FAH) raised the question of cell fusion. A fusion of mouse and human cells, like the one observed for murine bone marrow and hepatocytes (17) , is likely to show a similar patchy staining pattern. In addition, it was recently shown that monkey cells from embryoid bodies repopulate livers of uPA mice by cell fusion (18) . However, our in situ hybridization results show that engraftment and repopulation of human hepatocytes into fah Ϫ/Ϫ mice is not because of cell fusion. This result is in agreement with the recent work of Azuma et al. (10) .
Furthermore, we show that human hepatocytes can be readily transduced ex vivo as previously described (19, 20) . More important, the transgene is robustly expressed in vivo after transplantation. This proof of principle experiment shows that this animal model is suitable for transduction and sustained expression of genes by viral vectors.
In the present study, we further show efficient transplantation (73% of injected pups) of human hepatocytes into neonatal livers. The neonatal liver has many more dividing hepatocytes than the adult liver. This proliferative environment might be beneficial for the expansion of the engrafted human hepatocytes. Because the intrasplenic hepatocyte transplantation is technically challenging at birth, we developed an alternative intrahepatic transplantation method for human hepatocytes. Previously, it was shown that hematopoetic stem cells can be transplanted through intrahepatic injection of neonates (21) . Encouraged by this study, we explored human hepatocyte transplantation through intrahepatic injections. This method is technically easier than the traditional intrasplenic method and should encourage widespread use. We observed engraftment over the entire LLL, not only at the site of injection. The engraftment and expansion pattern is comparable to the intrasplenic hepatocyte transplantation, and repopulation rates up to 50% also can be observed within the injected lobe. Because the repopulation is restricted to the LLL, which is 35% of the liver, the estimated amount of human hepatocytes was significantly lower (7%) than seen with intrasplenic transplantation (20%) 3 months after transplanta-tion. However, it is conceivable to inject at least two other lobes (right and left upper lobes), which would add up to two thirds of the liver.
One advantage of the neonatal intrahepatic transplantation is that animals do not have postsurgical adhesions. Adhesions are rarely harmful to the animals, but often limit further surgical interventions. Unlike most of the intrasplenically transplanted animals, partial hepatectomy is more manageable after neonatal transplantation.
After our experimental work had concluded, Azuma et al. (10) described the successful transplantation of human hepatocytes into fah Ϫ/Ϫ mice preconditioned with an adenovirus-expressing uPA. The primary difference in their study and ours is that we did not need the additional step of treatment with adenovirusexpressing uPA. This manipulation will limit the use of these transplanted mice for further manipulation with adenoviral vectors because of prior antibodies generated by transduction with adeno uPA vector. Like in the study by Azuma et al. (10) , the reconstituted human hepatocytes in our study did not fuse with mouse hepatocytes. Additionally, we were able to show that human hepatocytes can be transduced with lentiviral vectors containing GFP and that expression was sustained after transplantation. Clearly, it is desirable to enhance the extent of human hepatocytes in transplanted mice.
In conclusion, we demonstrate that the fah Ϫ/Ϫ /rag-2 Ϫ/Ϫ / il-2rg Ϫ/Ϫ triple KO mouse is a suitable recipient for human hepatocyte transplantation without any additional pre-or posttransplantational treatments. We show that repopulation with human hepatocyte is independent of cell fusion and that foreign genes can be efficiently expressed after viral transduction. Furthermore, we developed a simple neonatal transplantation method that leads to an efficient repopulation of human hepatocytes into the murine liver. Mice reconstituted with human hepatocytes offer the opportunity to study drug metabolism and pursue gene therapy strategies.
Materials and Methods
Mice. The fah Ϫ/Ϫ mouse (8) was crossed with the il-2rg Ϫ/Ϫ (B6.129S4-Il2rgtm1Wjl/J) from The Jackson Laboratory and the rag-2 Ϫ/Ϫ mouse (RagN12) from Taconic Farms. Genotyping was done with the same primers and conditions as described elsewhere (8) or according to the protocols provided by vendors. Mice were kept on 7.5 mg/ml NTBC (100%) in the drinking water. Mice were kept in temperature-and humidity-controlled animal quarters with a 12-h light-dark cycle.
Transplantation of Adult and Neonatal Mice. Hepatocytes were purchased from CellzDirect. Hepatocytes were shipped as cell pellets on ice in the manufacturer's medium. Upon arrival, cells were washed once with 50 ml of HBM (Cambrex Bio Science) and kept on ice until transplantation (within 48 h after isolation). Adult mice were transplanted as previously described (16) . In short, mice were anesthetized with isoflurane during the whole procedure and kept on a heating pad. Then a mid-abdominal incision was performed, and the spleen was prepared for injection. The lower pole of the spleen was injected with 200 l of 0.2-1 ϫ 10 6 hepatocytes with a 27-gauge syringe. Thereafter, the injection site was ligated. Closing of the abdominal muscle layer was performed with 4 -0 silk sutures, and the skin was stapled. NTBC was immediately withdrawn (25%, 12%, and 6% of 7.5 mg/ml colony maintenance concentration, each step for 2 days before stopping the drug). After 7-10 days, mice were put again on NTBC for 3 days before second withdrawal (cycling). Depending on weight development or ELISA levels of human blood proteins, mice were cycled for several more rounds.
Neonates were transcutaneously injected with 50 l of 0.5-1 ϫ 10 6 hepatocytes into the left lower lobe with a 27-gauge syringe. NTBC was withdrawn, as described earlier, immediately after transplantation until 6%. Then we transferred the pups to a fostering ICR female and discontinued the drug completely. The mice were cycled on NTBC in the following steps: 100%, 25%, 12%, 6%, 0%, 100%, 25%, and so on. All animal procedures were performed in compliance with American animal welfare laws and regulations and were approved by our Institutional Animal Care and Use Committee. 
